Europska Unija - hrvatski - EMA (European Medicines Agency)

biomarin international limited - vosoritide - achondroplasia - lijekovi za liječenje bolesti kostiju - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.